90Y radioembolization of colorectal hepatic metastases using glass microspheres: Safety and survival outcomes from a 531-patient multicenter study

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 665-671

  Hickey, Ryan ^a   Lewandowski, Robert J ^a   Prudhomme, Totianna ^b   Ehrenwald, Eduardo ^b   Baigorri, Brian ^c   Critchfield, Jeffrey ^c   Kallini, Joseph ^a   Gabr, Ahmed ^a   Gorodetski, Boris ^d   Geschwind, Jean Francois ^d   Abbott, Andrea ^e   Shridhar, Ravi ^e   White, Sarah B ^f   Rilling, William S ^f   Boyer, Brendan ^g   Kauffman, Shannon ^g   Kwan, Sharon ^h   Padia, Siddarth A ^h   Gates, Vanessa L ^a   Mulcahy, Mary ⁱ   Kircher, Sheetal ⁱ   Nimeiri, Halla ⁱ   Benson, Al B ⁱ   Salem, Riad ^a,i   more..

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g MIAMI VALLEY HOSPITAL   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

90Y; Colorectal metastases; Radioembolization; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; BIOLOGICAL PRODUCT; CETUXIMAB; FLUOROURACIL; GLASS; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; YTTRIUM 90; MICROSPHERE; YTTRIUM;

ABDOMINAL PAIN; AGED; ARTICLE; ARTIFICIAL EMBOLIZATION; CANCER SURVIVAL; CHILL; COHORT ANALYSIS; COLORECTAL LIVER METASTASIS; DIARRHEA; DISEASE SEVERITY; DOSIMETRY; DRUG EXPOSURE; FATIGUE; FEMALE; FEVER; HEALTH STATUS; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOEMBOLIZATION; REPRODUCIBILITY; RETROSPECTIVE STUDY; SAFETY; TREATMENT PLANNING; UNIVARIATE ANALYSIS; VOMITING; ADVERSE EFFECTS; CHEMISTRY; CLINICAL TRIAL; COLORECTAL TUMOR; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIOMETRY; SECONDARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; GLASS; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOMETRY; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84966775474     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.166082     Document Type: Article

References (33)

1. Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol. 2015;22:794-802.
2. Lewandowski RJ, Memon K, Mulcahy MF, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: Survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1861-1869.
3. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
4. Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265-278.
5. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571-592.
6. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A stateof-the-art brachytherapy treatment for primary and secondary liver malignancies- part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17: 1251-1278.
7. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A stateof-the-art brachytherapy treatment for primary and secondary liver malignancies- part 2: Special topics. J Vasc Interv Radiol. 2006;17:1425-1439.
8. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: A stateof-the-art brachytherapy treatment for primary and secondary liver malignancies- part 3: Comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571-1593.
9. Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007;10:12-29.
10. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: Radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(suppl):S223-S229.
11. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-298.
12. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-592.
13. Venook APND, Lenz H, Innocenti F, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Presented at: ASCO annual meeting; Chicago, IL; 2014.
14. Lenz HND, Innocenti F, Blanke C, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Presented at: ESMO meeting; Madrid, Spain; 2014.
15. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-312.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
17. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048.
18. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii1-iii9.
19. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIRSpheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78-85.
20. Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687-3694.
21. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35:1066-1073.
22. Benson AB III, Geschwind JF, Mulcahy MF, et al. Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013;49:3122-3130.
23. Home page. SIRTeX.com website. http://www.sirtex.com. Accessed January 28, 2016.
24. About TheraSphere. TheraSphere.com website. http://www.therasphere.com. Accessed January 28, 2016.
25. NCCN clinical practice guidelines in oncology: Colon cancer, version 2.2015. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed January 28, 2016.
26. Welcome to the enhanced peri-operative care for high-risk patients (EPOCH) trial site. Epochtrial.org website. http://www.epochtrial.org/epoch.php. Accessed January 28, 2016.
27. FOLFOX plus SIR-SPHERES MICROSPHERES versus FOLFOX alone in patients with liver mets from primary colorectal cancer (SIRFLOX). ClinicalTrials. gov website. https://clinicaltrials.gov/ct2/show/NCT00724503. Accessed January 28, 2016.
28. FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid 1/2 Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer. ISRCTN registry website. http://www.controlled-trials.com/ISRCTN83867919. Accessed January 28, 2016.
29. Study design. Foxfire Global website. http://foxfireglobal.sirtex.com/study-design. Accessed January 28, 2016.
30. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): Assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522-529.
31. Sofocleous CT, Garcia AR, Pandit-Taskar N, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13:27-36.
32. Hickey R, Mulcahy MF, Lewandowski RJ, et al. Chemoradiation of hepatic malignancies: Prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88: 1025-1031.
33. Hamoui N, Minocha J, Memon K, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol. 2013;24: 1743-1745.